Elevated fasting plasma C‐peptide occurs in non‐diabetic individuals with fatty liver, irrespective of insulin resistance

Aims  Studies have pointed to insulin resistance as a pathogenic factor in fatty liver. Although pancreatic B‐cell function is believed to be involved, its role is unclear. This study was undertaken to test whether fasting C‐peptide, an index of fasting B‐cell function, was related to intra‐hepatic fat (IHF) content in non‐diabetic humans.

[1]  P. Pouwels,et al.  Lack of association of liver fat with model parameters of beta-cell function in men with impaired glucose tolerance and type 2 diabetes. , 2008, European journal of endocrinology.

[2]  K. Pietiläinen,et al.  Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  P. Scifo,et al.  Serum resistin and hepatic fat content in nondiabetic individuals. , 2006, The Journal of clinical endocrinology and metabolism.

[4]  S. Kahn,et al.  Review: The role of insulin resistance in nonalcoholic fatty liver disease. , 2006, The Journal of clinical endocrinology and metabolism.

[5]  D. Accili,et al.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. , 2006, The Journal of clinical investigation.

[6]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[7]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[8]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[9]  S. Grundy,et al.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.

[10]  P. Macfarlane,et al.  Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. , 2004, Diabetes.

[11]  P. Iozzo,et al.  Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[13]  A. Mari,et al.  Beta cell function and its relation to insulin action in humans: a critical appraisal , 2004, Diabetologia.

[14]  M. Beylot,et al.  Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. , 2003, Diabetes & metabolism.

[15]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[16]  M. Roden,et al.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.

[17]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[18]  C. Bogardus,et al.  High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.

[19]  G. Lewis,et al.  Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. , 2002, Endocrine reviews.

[20]  A. Caumo,et al.  Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. , 2001, The Journal of clinical endocrinology and metabolism.

[21]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[22]  V. Mazzaferro,et al.  Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation , 2000, Hepatology.

[23]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[24]  S. Wannamethee,et al.  Prospective Study of Serum γ-Glutamyltransferase and Risk of NIDDM , 1998, Diabetes Care.

[25]  E. Ferrannini,et al.  Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). , 1997, The Journal of clinical investigation.

[26]  C. Tiribelli,et al.  Fatty Infiltration of the Liver: Quantification by 1H Localized Magnetic Resonance Spectroscopy and Comparison with Computed Tomography , 1993, Investigative radiology.

[27]  R. Shulman,et al.  Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.

[28]  Jeppe Sturis,et al.  Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance , 1992, Diabetes.

[29]  C. Cobelli,et al.  Glucose disposal, beta-cell secretion, and hepatic insulin extraction in cirrhosis: a minimal model assessment. , 1990, Gastroenterology.

[30]  X. Papademetris,et al.  Inaugural Article: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome , 2007 .

[31]  S. Wild,et al.  Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects , 2005, Diabetologia.

[32]  J. Schwarz,et al.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. , 2003, The American journal of clinical nutrition.

[33]  S. Wannamethee,et al.  Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. , 1998, Diabetes care.

[34]  C. Thomsen,et al.  Quantification of liver fat using magnetic resonance spectroscopy. , 1994, Magnetic resonance imaging.

[35]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.